Disclaimer
The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
We are a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease and heart failure.
alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove this excess fluid. While DSR is still in development, alfapump® is delivering clinical and quality of life benefits for patients and reducing costs for healthcare systems. We are listed on Euronext Brussels, headquartered in Ghent, Belgium and also have offices in Zurich, Switzerland.
We embrace diversity and inclusion. You will have the opportunity to work with outstanding business teams and contribute to the success of the company. We strive to provide all our employees with the means to develop their skills and experiences, at every level.
Sequana Medical is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer, when diuretics are no longer effective. alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove the excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems.
We are looking for a technically skilled, hands-on individual to join our small and dynamic manufacturing team in Zurich as a Production Assembler.
As a Production Assembler, you will assemble and test our implantable pump, catheters, and accessories according to defined procedures.
The work is primarily carried out in a clean room, often under a microscope.
Does this opportunity sound exciting?
Join our great team responsible for manufacturing high-tech medical devices that improve quality of life!
Does this opportunity sound exciting? Join our dynamic team in Ghent!
Apply via Linkedin or send your CV and full application (in Dutch or English) to careers@sequanamedical.com.
Alternatively, you can submit your application via the dedicated form here.
We look forward to hearing from you!
Are you passionate about advanced electronic systems that make a real impact in the medical technology field?
We are looking for a Medical Device Engineer Electronics to join our Engineering team in Zurich.
In this role, you will act as a subject matter expert in electronics and embedded systems for active implantable medical devices.
You will be responsible for the full life-cycle management of electronic components, from design to performance analysis and verification. You’ll collaborate closely with cross-functional teams, including Regulatory Affairs and Manufacturing, ensuring technical excellence and compliance across the entire product life cycle.
We’re seeking a motivated, detail-oriented professional with strong analytical skills, excellent communication abilities, and a structured, quality-driven mindset.
Help shape the future of healthcare technology and apply now to join a team dedicated to improving lives through innovation!
Does this opportunity sound exciting? Join our dynamic team in Ghent!
Apply via Linkedin or send your CV and full application (in Dutch or English) to careers@sequanamedical.com.
Alternatively, you can submit your application via the dedicated form here.
We look forward to hearing from you!
[2] Quality of life as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)
[1] POSEIDON study results in SSED (PMA P230044, FDA approval letter on file) – 100% median reduction in number of therapeutic paracentesis per month in Pivotal Cohort
Estes et al. (2018)
Ginès et al. (2004) (déclarant que l’ascite réfractaire apparaît chez 5 à 10% des patients souffrant d’ascite)
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370
Kilgore et al. (2017); Ambrosy et al. (2014)
Kilgore et al. (2017)
Costanzo et al. (2007)
Benjamin et al. (2013)
Ayantunde et al. (2006)
World Health Organization International Agency for Research on Cancer 2018 (website) (estimated number of new breast and ovarian cases in 2018 (crude rate))
European Association for the Study of the Liver. EASL clinical practice guideliones on the management of ascites, spontane bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402
Runyon et al. (2009)
GlobalData NASH Epidemiology Forecast to 2026
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (web site)

United States
Stay on sequanamedical.com

Europe
Go to alfapump.com
